niacinamide and Small Cell Lung Carcinoma

niacinamide has been researched along with Small Cell Lung Carcinoma in 4 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Small Cell Lung Carcinoma: A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).

Research

Studies (4)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST)

Complete Response (CR) is a complete disappearance of all measurable and non-measurable disease. No new lesions, no disease related symptoms. Normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration. (NCT00182689)
Timeframe: 8 weeks to 2 years

Overall Survival

Measured from time of registration to death, or last contact date (NCT00182689)
Timeframe: 0 - 2 years

Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug

Adverse Events (AEs) are reported by the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal. (NCT00182689)
Timeframe: Patients were assessed for adverse events after completion of every 28-day cycle.

Overall Survival

Estimated to within at least 15% (95% confidence interval). (NCT00828139)
Timeframe: Weekly, up to 2 years.

Progression-free Survival (PFS)

"From the date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause.~Progression is defined as 20% increase in the sum of longest diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided). Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration." (NCT00828139)
Timeframe: Disease assessments were performed every 6 weeks, up to 2 years.

Response Rate (Confirmed and Unconfirmed, Complete and Partial Responses)

"The number of confirmed and unconfirmed complete and partial responses in the subset of patients with measurable disease per RECIST 1.0. Estimated to within at least 17% (95% confidence interval).~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by magnetic resonance imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00828139)
Timeframe: Disease assessment for response were performed every 6 weeks, up to 2 years.

Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drugs

Adverse Events (AEs) are reported by CTCAE Version 3.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. The events listed here are not necessary to be included in Serious Adverse Event. A serious event could be death, life-threatening, hospitalization, disability or permanent damage, congenital anomaly...Grade 3 through 5 adverse event may not meet the criterion of serious adverse event. (NCT00828139)
Timeframe: Toxicity assessment was evaluated after each cycle (21 days), up to 2 years.

Trials

3 trials available for niacinamide and Small Cell Lung Carcinoma

Other Studies

1 other study available for niacinamide and Small Cell Lung Carcinoma